Pharmacodynamics of daily subcutaneous recombinant human interleukin-3 in normal volunteers

Richard D. Huhn; Edward J. Yurkow; John G. Kuhn; Laura Clarke; Han Gunn; Debra Resta; Reena Shah; Laurie A. Myers; James R. Seibold

doi:10.1016/0009-9236(95)90263-5

Pharmacodynamics of daily subcutaneous recombinant human interleukin-3 in normal volunteers

Richard D. Huhn, Edward J. Yurkow, John G. Kuhn, Laura Clarke, Han Gunn, Debra Resta, Reena Shah, Laurie A. Myers, James R. Seibold

RUBRIC

Research output: Contribution to journal › Article › peer-review

11 Scopus citations

Abstract

Normal volunteers received subcutaneous injections of recombinant human interleukin-3 (rhIL-3) on 4 consecutive days to characterize toxicity, pharmacokinetics, and hematopoietic effects. Dosage were 2.5, 5.0, and 7.5 μg/kg/day (n = 6 subjects per group). Adverse effects consisted predominantly of flu-like symptoms such as fever and headache. Mean area under the serum concentration-time curve and maximum serum concentration were linearly related to dose. Serum clearance was not apparently related to dose. Clearance increased slightly but significantly between days 1 and 4. Rapid but modest elevations in neutrophil and eosinophil counts were observed during treatment. Mean platelet counts rose modestly, peaking on day 10. Increases of CD34⁺ cell counts were correlated with increases of colony-forming unit-granulocyte macrophage (peak, day 7).

Original language	English (US)
Pages (from-to)	32-41
Number of pages	10
Journal	Clinical pharmacology and therapeutics
Volume	57
Issue number	1
DOIs	https://doi.org/10.1016/0009-9236(95)90263-5
State	Published - Jan 1995

All Science Journal Classification (ASJC) codes

Pharmacology
Pharmacology (medical)

Access to Document

10.1016/0009-9236(95)90263-5

Cite this

@article{448fdd97ff4c4da8bb9a5a6a3b5c562d,

title = "Pharmacodynamics of daily subcutaneous recombinant human interleukin-3 in normal volunteers",

abstract = "Normal volunteers received subcutaneous injections of recombinant human interleukin-3 (rhIL-3) on 4 consecutive days to characterize toxicity, pharmacokinetics, and hematopoietic effects. Dosage were 2.5, 5.0, and 7.5 μg/kg/day (n = 6 subjects per group). Adverse effects consisted predominantly of flu-like symptoms such as fever and headache. Mean area under the serum concentration-time curve and maximum serum concentration were linearly related to dose. Serum clearance was not apparently related to dose. Clearance increased slightly but significantly between days 1 and 4. Rapid but modest elevations in neutrophil and eosinophil counts were observed during treatment. Mean platelet counts rose modestly, peaking on day 10. Increases of CD34+ cell counts were correlated with increases of colony-forming unit-granulocyte macrophage (peak, day 7).",

author = "Huhn, {Richard D.} and Yurkow, {Edward J.} and Kuhn, {John G.} and Laura Clarke and Han Gunn and Debra Resta and Reena Shah and Myers, {Laurie A.} and Seibold, {James R.}",

year = "1995",

month = jan,

doi = "10.1016/0009-9236(95)90263-5",

language = "English (US)",

volume = "57",

pages = "32--41",

journal = "Clinical Pharmacology and Therapeutics",

issn = "0009-9236",

publisher = "Nature Publishing Group",

number = "1",

}

TY - JOUR

T1 - Pharmacodynamics of daily subcutaneous recombinant human interleukin-3 in normal volunteers

AU - Huhn, Richard D.

AU - Yurkow, Edward J.

AU - Kuhn, John G.

AU - Clarke, Laura

AU - Gunn, Han

AU - Resta, Debra

AU - Shah, Reena

AU - Myers, Laurie A.

AU - Seibold, James R.

PY - 1995/1

Y1 - 1995/1

N2 - Normal volunteers received subcutaneous injections of recombinant human interleukin-3 (rhIL-3) on 4 consecutive days to characterize toxicity, pharmacokinetics, and hematopoietic effects. Dosage were 2.5, 5.0, and 7.5 μg/kg/day (n = 6 subjects per group). Adverse effects consisted predominantly of flu-like symptoms such as fever and headache. Mean area under the serum concentration-time curve and maximum serum concentration were linearly related to dose. Serum clearance was not apparently related to dose. Clearance increased slightly but significantly between days 1 and 4. Rapid but modest elevations in neutrophil and eosinophil counts were observed during treatment. Mean platelet counts rose modestly, peaking on day 10. Increases of CD34+ cell counts were correlated with increases of colony-forming unit-granulocyte macrophage (peak, day 7).

AB - Normal volunteers received subcutaneous injections of recombinant human interleukin-3 (rhIL-3) on 4 consecutive days to characterize toxicity, pharmacokinetics, and hematopoietic effects. Dosage were 2.5, 5.0, and 7.5 μg/kg/day (n = 6 subjects per group). Adverse effects consisted predominantly of flu-like symptoms such as fever and headache. Mean area under the serum concentration-time curve and maximum serum concentration were linearly related to dose. Serum clearance was not apparently related to dose. Clearance increased slightly but significantly between days 1 and 4. Rapid but modest elevations in neutrophil and eosinophil counts were observed during treatment. Mean platelet counts rose modestly, peaking on day 10. Increases of CD34+ cell counts were correlated with increases of colony-forming unit-granulocyte macrophage (peak, day 7).

UR - http://www.scopus.com/inward/record.url?scp=0028893806&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028893806&partnerID=8YFLogxK

U2 - 10.1016/0009-9236(95)90263-5

DO - 10.1016/0009-9236(95)90263-5

M3 - Article

C2 - 7828379

AN - SCOPUS:0028893806

SN - 0009-9236

VL - 57

SP - 32

EP - 41

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

IS - 1

ER -

Pharmacodynamics of daily subcutaneous recombinant human interleukin-3 in normal volunteers

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this